BREAKING
Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 hour ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 3 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 5 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 6 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 7 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 7 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 10 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 10 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 11 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 11 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 hour ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 3 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 5 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 6 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 7 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 7 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 10 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 10 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 11 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 11 hours ago
ADVERTISEMENT
Market News

Amarin Corporation (AMRN): Q4 2019 Earnings Snapshot

— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected.   — Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US.  — For full-year 2020, Amarin […]

$AMRN February 25, 2020 1 min read
Amarin Q4 earnings

— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected.  

— Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US. 

— For full-year 2020, Amarin expects revenues to be $650 million to $700 million.

— AMRN shares gained 2% during the aftermarket hours. 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

ADVERTISEMENT
ADVERTISEMENT